Adding chemo to osimertinib does not stop small cell transformation in high-risk EGFR lung cancer
- A prospective trial gave first-line osimertinib with platinum and etoposide to EGFR-mutant lung adenocarcinoma patients carrying TP53/RB1 co-mutations, who are prone to small cell transformation.
- Despite the SCLC-directed chemotherapy, nearly half of the small cohort still transformed.
- Genomic and single-cell profiling showed plasticity, including mesenchymal and squamous states, tied to progressive RB pathway loss, altered chromatin accessibility and neuronal and EMT programs, intensified by osimertinib.
💡 Points Based on the abstract
If SCLC-style chemo can't hold back transformation, the problem is likely lineage plasticity rather than an untreated small cell clone, so the next step is testing the drivers directly: RB pathway restoration, or epigenetic and neuronal-program inhibition. Without an osimertinib-alone comparator, "nearly half" is hard to read against baseline transformation risk. Serial biopsies or ctDNA would show whether RB loss precedes transformation.
📄 Paper · Science Translational Medicine ↗ Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation